HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarBacktestsPricing
Theme
Help Login Register
Market News Stocks News ETF News Crypto News

Qualigen Therapeutics, Inc.

Contributing Author

Recent Articles by Qualigen Therapeutics, Inc.

Oct-12
Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For? QLGN GlobeNewswire
Oct-06
Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor Transition QLGN GlobeNewswire
Sep-30
Qualigen Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation into Crypto QLGN GlobeNewswire
Sep-19
Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE Transaction QLGN GlobeNewswire
Jul-28
Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing Status QLGN GlobeNewswire
Jul-28
Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock QLGN GlobeNewswire
Jul-16
Qualigen Granted New Patents Covering 25 Countries QLGN GlobeNewswire
May-19
Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q QLGN GlobeNewswire
May-01
Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K QLGN GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.

Learn more about FINVIZ*Elite